<DOC>
	<DOCNO>NCT02509286</DOCNO>
	<brief_summary>The trial design investigate difference outcome patient esophageal adenocarcinoma junctional adenocarcinoma treat perioperative ( neoadjuvant + adjuvant ) chemotherapy ( FLOT ) plus surgical resection versus neoadjuvant chemoradiation ( CROSS ) plus surgical resection .</brief_summary>
	<brief_title>Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation Patients With Adenocarcinoma Esophagus</brief_title>
	<detailed_description>According give evidence survival benefit perioperative chemotherapy ( periCTX ) Neoadjuvant chemoradiation ( neoCRT ) patient Esophageal adenocarcinoma ( EAC ) proven randomize control trial ( RCT ) . Data support value periCTX obtain study include mixed patient cohort EAC gastric adenocarcinoma ( GAC ) . Due relevant difference histologic subtype distribution , response periCTX survival rate EAC GAC clear need obtain evidence concern value periCTX EAC . As nowadays periCTX extensively successfully applied clinical practice patient EAC obvious need obtain evidence multicentre RCT . Moreover confirmation superior survival rate recent RCT neoCRT obtain RCT conduct exclusively EAC . Therefore , prospective RCT primary objective longterm patient survival compare periCTX neoCRT design .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion criterion : Histologically verify adenocarcinoma esophagus accord UICC definition ( TNM7 ) Pretreatment stage cT1N+ , M0 cT24a , N0/+ , M0 Age â‰¥18 year No prior abdominal thoracic radiotherapy ECOG Performance status 02 Adequate cardiac function ( Patients cardiac history ( e.g . myocardial infarction , heart failure , coronary artery disease ) cardiology review ) Adequate bone marrow function ( WBC &gt; 3x10^9/l ; Hb &gt; 9g/dl ; platelet &gt; 100x10^9/l ) Adequate respiratory function . Symptomatic Patients pulmonary function test FEV1 &gt; 1,5l ) Adequate renal function ( GFR &gt; 60ml/min ) Adequate liver function ( serum bilirubin &lt; 1.5x Upper level Normal ( ULN ) ; AST &lt; 2.5x ULN ALT &lt; 3x ULN ( ULN per institutional standard ) write informed consent Tumors squamous nonadenocarcinoma histology Patients advance inoperable metastatic esophageal adenocarcinoma Stage cT1N0 cT4b Gastric carcinoma Prior chemotherapy cancer , Clinically significant ( i.e . active ) cardiac disease ( e.g . symptomatic coronary artery disease myocardial infarction within last 12 month ) Clinical significant lung disease ( FEV 1 &lt; 1,5l ) Peripheral neuropathy Grade &gt; 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Esophageal neoplasm</keyword>
	<keyword>gastro-esophageal junction neoplasm</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>esophagectomy</keyword>
	<keyword>surgery</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
</DOC>